CONCORD, Calif.--(BUSINESS WIRE)--Cerus Corporation (NASDAQ:CERS) announced today that the German Red Cross Blood Donor Service in the Baden-Württemberg – Hessen region (DRK BWH), including Frankfurt, has been granted authorization by the Paul Ehrlich Institute (PEI) to market platelet components treated with the INTERCEPT Blood System. The marketing authorization covers pooled platelets using the buffy coat method of collection. A marketing authorization covering platelets collected from single donors by apheresis was granted in late February 2009. The DRK BWH is one of the large Red Cross Blood Donor Services in Germany, collecting and processing approximately 25% of the blood supply in Germany.
